Lomustine
From Wikipedia, the free encyclopedia
|
Lomustine
|
|
| Systematic (IUPAC) name | |
| 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C9H16ClN3O2 |
| Mol. mass | 233.695 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 50% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Lomustine (or "CCNU")(Marketed under the name CeeNU in US) is an alkylating nitrosourea compound used in chemotherapy. It is in the same family as streptozotocin. This is a highly lipid soluble drug, and thus crosses the blood brain barier. This property makes it ideal for treating brain tumors, and is its primary use. Lomustine has a long time to nadir (the time when white blood cells reach their lowest number).
Contents |
[edit] Dose:
Adults: 100-150mg/m2 PO every 6 weeks (subsequent dose based on WBC) [1]
[edit] Dosage Form:
10mg, 40mg, 100mg Capsules
[edit] Other
It is the "C" in the "PCV" chemotherapy regimen.

